Lv1
60 积分 2024-12-07 加入
Population Norms for SF-6Dv2 and EQ-5D-5L in China
2个月前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
2个月前
已完结
Incidence of First-Ever Stroke, Stroke Events, and Early Case Fatality Rate in China: Results from a National Population-Based Survey
2个月前
已完结
Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy
2个月前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
2个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
2个月前
已完结
Case-fatality, disability and recurrence rates after first-ever stroke: A study from bigdata observatory platform for stroke of China
2个月前
已完结
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
2个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
3个月前
已完结
皖公网安备34019202002308
